Literature DB >> 26601667

The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.

Kazuya Okushin1, Takeya Tsutsumi2, Kenichiro Enooku1, Hidetaka Fujinaga1, Akira Kado1, Junji Shibahara3, Masashi Fukayama3, Kyoji Moriya4, Hiroshi Yotsuyanagi2, Kazuhiko Koike5.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) presents as a spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). The latter is progressive, and its pathogenesis remains poorly understood. Recently, bile acid (BA) metabolism has become a therapeutic focus in NASH patients. The aim of the present study was to explore changes in bile acid metabolism in NAFLD patients in the context of disease progression.
METHODS: We prospectively enrolled patients with clinically suspected NAFLD. Patients taking ursodeoxycholic acid were excluded. The intrahepatic expression levels of genes associated with BA metabolism were determined by quantitative PCR and immunohistochemistry.
RESULTS: Seventy-eight patients (male:female = 49:29) histologically diagnosed with NAFLD were analyzed. The expression levels of farnesoid X receptor, liver receptor homolog 1, and small heterodimer partner, key proteins in BA synthesis, significantly decreased as the NAFLD activity score (NAS) increased in either males or females. The levels of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme of BA synthesis, were not changed. Notably, the expression levels of a main export transporter, bile salt export pump (BSEP), significantly decreased as the NAS and the each NAS component increased in both genders. The decreases of BSEP levels were also observed by immunohistochemistry, particularly in areas with pronounced fatty changes in cases with high NAS.
CONCLUSIONS: The expression levels of the BA export transporter BSEP were inversely correlated with NAS in NAFLD patients. Such down-regulation may cause excessive BA levels in hepatocytes, leading to cell injury. Our findings may afford new insights into the pathogenesis of NASH.

Entities:  

Keywords:  Bile acid; Nonalcoholic fatty liver disease; Transporter

Mesh:

Substances:

Year:  2015        PMID: 26601667     DOI: 10.1007/s00535-015-1148-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  31 in total

1.  Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background.

Authors:  Sei-Ichiro Kojima; Norihito Watanabe; Makoto Numata; Tetsuhei Ogawa; Shohei Matsuzaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

2.  Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors:  B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2015-03-15       Impact factor: 6.875

3.  Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.

Authors:  Zhao-Xia Yang; Wei Shen; Hang Sun
Journal:  Hepatol Int       Date:  2010-08-12       Impact factor: 6.047

Review 4.  Genetic variations of bile salt transporters.

Authors:  Ralf Kubitz; Carola Dröge; Stefanie Kluge; Jan Stindt; Dieter Häussinger
Journal:  Drug Discov Today Technol       Date:  2014-06

5.  Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Yu Yang; Arthur J McCullough; Susan Marczewski; Carole Bennett; Satish C Kalhan
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-05       Impact factor: 2.566

6.  Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.

Authors:  Lars P Bechmann; Peri Kocabayoglu; Jan-Peter Sowa; Svenja Sydor; Jan Best; Martin Schlattjan; Anja Beilfuss; Johannes Schmitt; Rebekka A Hannivoort; Alpaslan Kilicarslan; Christian Rust; Frieder Berr; Oliver Tschopp; Guido Gerken; Scott L Friedman; Andreas Geier; Ali Canbay
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

Review 7.  Gut-liver axis in alcoholic liver disease.

Authors:  Gyongyi Szabo
Journal:  Gastroenterology       Date:  2014-11-11       Impact factor: 22.682

8.  The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.

Authors:  Nancy E Aguilar-Olivos; Daniel Carrillo-Córdova; Jesús Oria-Hernández; Vicente Sánchez-Valle; Guadalupe Ponciano-Rodríguez; Manuel Ramírez-Jaramillo; Fredy Chablé-Montero; Norberto C Chávez-Tapia; Misael Uribe; Nahum Méndez-Sánchez
Journal:  Ann Hepatol       Date:  2015 Jul-Aug       Impact factor: 2.400

Review 9.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

10.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

View more
  15 in total

1.  Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.

Authors:  Kenichiro Enooku; Takeya Tsutsumi; Mayuko Kondo; Naoto Fujiwara; Takayoshi Sasako; Junji Shibahara; Akira Kado; Kazuya Okushin; Hidetaka Fujinaga; Ryo Nakagomi; Tatsuya Minami; Masaya Sato; Koji Uchino; Hayato Nakagawa; Yuji Kondo; Yoshinari Asaoka; Ryosuke Tateishi; Kohjiro Ueki; Hitoshi Ikeda; Haruhiko Yoshida; Kyoji Moriya; Hiroshi Yotsuyanagi; Takashi Kadowaki; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2019-10-10       Impact factor: 7.527

Review 2.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

Review 3.  Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations.

Authors:  Solène Marie; David K K Tripp; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2021-09-16       Impact factor: 3.579

4.  Reversal of NAFLD After VSG Is Independent of Weight-Loss but RYGB Offers More Efficacy When Maintained on a High-Fat Diet.

Authors:  Ankita Srivastava; Matthew Stevenson; Jenny Lee; Christopher Hall; Thomas Palaia; Chaohui Lisa Zhao; Raymond Lau; Collin Brathwaite; Louis Ragolia
Journal:  Obes Surg       Date:  2022-04-14       Impact factor: 3.479

5.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

6.  Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.

Authors:  Akira Kado; Takeya Tsutsumi; Kenichiro Enooku; Hidetaka Fujinaga; Kazuhiko Ikeuchi; Kazuya Okushin; Kyoji Moriya; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2019-03-04       Impact factor: 7.527

Review 7.  Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.

Authors:  Juan P Arab; Saul J Karpen; Paul A Dawson; Marco Arrese; Michael Trauner
Journal:  Hepatology       Date:  2016-08-04       Impact factor: 17.425

8.  iPla2β Deficiency Suppresses Hepatic ER UPR, Fxr, and Phospholipids in Mice Fed with MCD Diet, Resulting in Exacerbated Hepatic Bile Acids and Biliary Cell Proliferation.

Authors:  Yanan Ming; Xingya Zhu; Sabine Tuma-Kellner; Alexandra Ganzha; Gerhard Liebisch; Hongying Gan-Schreier; Walee Chamulitrat
Journal:  Cells       Date:  2019-08-12       Impact factor: 6.600

9.  Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients.

Authors:  Kenichiro Enooku; Mayuko Kondo; Naoto Fujiwara; Takayoshi Sasako; Junji Shibahara; Akira Kado; Kazuya Okushin; Hidetaka Fujinaga; Takeya Tsutsumi; Ryo Nakagomi; Tatsuya Minami; Masaya Sato; Hayato Nakagawa; Yuji Kondo; Yoshinari Asaoka; Ryosuke Tateishi; Kohjiro Ueki; Hitoshi Ikeda; Haruhiko Yoshida; Kyoji Moriya; Hiroshi Yotsuyanagi; Takashi Kadowaki; Masashi Fukayama; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2018-05-10       Impact factor: 7.527

10.  PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease.

Authors:  Rajashree Rana; Andrew M Shearer; Elizabeth K Fletcher; Nga Nguyen; Srijoy Guha; Daniel H Cox; Manal Abdelmalek; Ying Wang; James D Baleja; Lidija Covic; Athan Kuliopulos
Journal:  Mol Metab       Date:  2019-08-28       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.